cyprotex
the ADME Tox specialists
home > ADME and PK services > plasma protein binding

Plasma Protein Binding Assay

Understand the distribution potential of your compound using our plasma protein binding assay.

Plasma protein binding is one of Cyprotex's in vitro ADME screening services. Cyprotex deliver consistent, high quality data with cost-efficiency that comes from a highly automated approach.
 

Determination of fraction unbound in plasma using equilibrium dialysis

  • The extent of binding to plasma influences the way in which a drug distributes into tissues in the body.
  • Extensive plasma protein binding also limits the amount of free compound available to access sites of action in the cell, and metabolism and elimination may be slower.
  • Equilibrium dialysis is the most widely accepted method for assessing plasma protein binding as non specific binding effects are minimized compared with other methods such as ultrafiltration.
  • Cyprotex's Plasma Protein Binding assay is performed using an equilibrium dialysis method and delivers a value of fraction of compound unbound to proteins (fu).
  • There is a choice of three methods for assessing plasma protein binding using three different percentages of plasma to provide flexibility depending on budget and compound characteristics.
  plasma protein binding
‘Equilibrium dialysis is the preferred method to determine the free drug fraction, because it is less susceptible to experimental artifacts.’
1Kariv I, Cao H and Oldenburg KR. (2001) J Pharm Sci 90 (5); 580-587.
Protocol +
Data +
Q&A +
References

1 Kariv I et al. (2001) J Pharm Sci 90 (5); 580-587.

2 Goodman and Gilman's (1996) The Pharmacological Basis of Therapeutics.

 
 
plasma protein binding

Download a copy of the product sheet

Cloe® is a registered trade mark owned by Cyprotex PLC

careerscontactlegalprivacy
This website was last updated
on 22nd April 2014
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.